

**REMARKS**

**I. Amendments**

The Sequence Listing is amended in accordance with 37 C.F.R. §§ 1.821 through 1.825.

The specification and claims are amended in accordance with 37 C.F.R. § 1.821(d) to include sequence identifiers.

No new matter is introduced by way of these amendments.


In light of the foregoing amendments to the application, Applicants submit that the application is now in full compliance with 37 C.F.R. §§ 1.821 through 1.825.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 07-1048 (Docket No. GC742-2-US).

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at the number listed below.

Respectfully submitted,

Date: June 18, 2008

  
Kamrin T. MacKnight  
Registration No. 38,230

Genencor Division, Danisco US, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304-1013  
Tel: 650-846-5838  
Fax: 650-845-6504